April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Acyclovir tablets, Major<br />
400 tablets, 100 count (NDC 00904-6121-61)<br />
Acyclovir capsules and tablets, Ranbaxy<br />
400 mg tablets, 100 count (NDC 63304-0504-01)<br />
800 mg tablets, 100 count (NDC 63304-0505-01)<br />
200 mg capsules, 100 count (NDC 63304-0652-01)<br />
200 mg capsules, 500 count (NDC 63304-0652-05) - discontinued<br />
Acyclovir capsules and tablets, Teva<br />
400 mg tablets, 100 count (NDC 00093-8943-01)<br />
400 mg tablets, 100 count, unit-dose (NDC 00093-8943-93)<br />
400 mg tablets, 500 count (NDC 00093-8943-05)<br />
800 mg tablets, 100 count (NDC 00093-8947-01)<br />
800 mg tablets, 100 count, unit-dose (NDC 00093-8947-93)<br />
800 mg tablets, 500 count (NDC 00093-8947-05)<br />
Reason for the Shortage<br />
Apotex has halted manufacturing due to an FDA audit.<br />
Ranbaxy has acyclovir capsules and tablets on back order due to a raw materials shortage.<br />
Teva and Major could not provide a reason for the shortage.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=591<br />
Source: www.ashp.org<br />
Prochlorperazine Edisylate Injection<br />
March 13, <strong>2012</strong><br />
Products Affected - Description<br />
Prochlorperazine injection 5 mg/mL, Bedford<br />
2 mL vial, 10 count (NDC 55390-0077-10)<br />
10 mL vial (NDC 55390-0077-01)<br />
Reason for the Shortage<br />
• Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011.<br />
Product will become available in stages as production resumes.<br />
• Bedford Laboratories has multiple products affected by this suspension of manufacturing.<br />
Availability of all products, including those not manufactured at Ben Venue, is updated as<br />
information changes on the Bedford Laboratories website.1<br />
• Bedford is the sole manufacturer of prochlorperazine injection.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=796<br />
Source: www.ashp.org<br />
Isradipine Oral Presentations<br />
March 13, <strong>2012</strong><br />
Products Affected - Description<br />
Dynacirc CR, GSK<br />
5 mg extended-release tablets, 30 count (NDC 00173-0784-01)<br />
10 mg extended-release tablets, 30 count (NDC 00173-0785-01)<br />
Reason for the Shortage<br />
• Novartis voluntarily suspended all manufacturing and distribution from its Lincoln, Nebraska<br />
facility in early-January <strong>2012</strong> due to a potential for mixing of different products within a single<br />
bottle. Novartis is gradually resuming manufacturing at this facility after manufacturing<br />
improvements were implemented.<br />
43
Change language